Heat Biologics (HTBX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Noble Financial Sees Multiple Readouts for Heat Biologics (HTBX) by YE16; Maintains 'Buy' Rating
August 17, 2016 11:25 AM EDTNoble Financial affirms Heat Biologics, Inc. (HTBX) with a Buy rating and $8 price target following recent Q2 results.
Analyst Kumaraguru Raja sees multiple readouts for Heat Bio by the end of the year. Key points include:
Potential candidate for acquisition or collaboration. ImPACT based clinical programs, HS-410 in non-muscle invasive bladder cancer (NMIBC), and... MoreRoth Capital Keeps Heat Biologics (HTBX) at 'Buy' at Q4 Inflection Points Near
August 16, 2016 10:01 AM EDTRoth Capital affirms Heat Biologics (Nasdaq: HTBX) at Buy with a price target of $2.75 following Q2 results issued on Monday.
Analyst Joseph Pantgninis noted that the company is moving quickly towards inflection points slated for Q416. The analyst commented:
Heat expects to report top-line data in 4Q16 for its Phase II trial evaluating HS-410 for the treatment of non-muscle invasive bladder cancer (NMIBC) and its Phase Ib trial evaluating HS-110 in... More
